Category: Lung Cancer

Patients with small-cell lung cancer who receive a course of radiation therapy to their heads after responding to chemotherapy live longer and are less likely to develop secondary brain tumours, a common feature of this disease, than those who are offered no further treatment, according to the re

The NPA is working with The Roy Castle Lung Cancer Foundation and Macmillan Cancer Support to promote November’s Lung Cancer Awareness Month through community pharmacy.NPA members will receive with their October InTouch (the NPA’s member magazine) an A4 ‘Lung Cancer Awareness’ poster for pharmacists to display in their shops.

Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX:), along with the Society for Women’s Health Research, the Lung Cancer Alliance and others, will support a panel discussion entitled “Lung Cancer: Being Female Matters to Research,” on Capitol Hill to discuss advances in the research and treatment of lung cancer in women on Monday, September 17.

Nearly a third of prostate biopsies resulted in a cancer diagnosis among a population of older men on Medicare. Men whose first biopsy did not find cancer often had multiple biopsies in the future, which increased the chance of a cancer diagnosis.While PSA (prostate-specific antigen) tests have become widely used in prostate cancer screening, a biopsy is what actually determines the presence of prostate cancer.

New evidenced-based guidelines from the American College of Chest Physicians (ACCP) recommend against the use of low-dose computed tomography (LDCT) for the general screening of lung cancer. Published as a supplement to the September issue of CHEST, the peer-reviewed journal of the ACCP, the guidelines cite there is little evidence to show lung cancer screening impacts mortality in patients, including those who are considered at high risk for the disease.

Alfacell Corporation (Nasdaq: ACEL) announced it has confirmed that 290 evaluable events (patient deaths) have occurred in the Phase IIIb clinical trial of its lead compound, ONCONASE, for the treatment of patients with unresectable malignant mesothelioma. The number of evaluable events was confirmed after the company learned that total events in the study had reached 316.

Merck KGaA announced that Erbitux® (cetuximab) combined with vinorelbine plus cisplatin met the primary endpoint of increasing overall survival compared with chemotherapy alone in a Phase III study initiated by Merck Serono in patients with advanced non-small cell lung cancer (NSCLC).

ImClone Systems Incorporated (Nasdaq: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that a Phase III study of ERBITUX(R) (Cetuximab) in combination with platinum-based chemotherapy (vinorelbine plus cisplatin) met its primary endpoint of increasing overall survival compared with chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC).

Amgen (NASDAQ:AMGN) presented the results from a randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of Aranesp(R) (darbepoetin alfa) in previously untreated patients with extensive-stage small-cell lung cancer (SCLC) receiving chemotherapy (”the 145 study”) on Monday, Sept. 3 at the 2007 World Conference on Lung Cancer in Seoul, Korea.

Boehringer Ingelheim announced from the 12th World Conference on Lung Cancer (WCLC) that the company plans to commence Phase III pivotal trials in lung cancer with BIBW 2992, its novel, second generation, potent, irreversibly binding, dual inhibitor of EGFR and HER2 and thereby further demonstrated its commitment to discovery and development of novel compounds in oncology.